These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1856515)

  • 1. Evidence of a correlation between CA15.3 and estradiol serum levels in women with fibrocystic (non macrocystic) mastopathy.
    Vizoso F; Allende MT; Diez MC; Ruibal A
    Int J Biol Markers; 1991; 6(1):33-4. PubMed ID: 1856515
    [No Abstract]   [Full Text] [Related]  

  • 2. [Correlations of serum concentrations of CA 15.3 and estradiol in women with breast macrocystic disease].
    Vizoso F; Allende MT; Fueyo A; Vivanco J
    Med Clin (Barc); 1990 May; 94(20):798. PubMed ID: 2392013
    [No Abstract]   [Full Text] [Related]  

  • 3. [Correlation between blood concentrations of CA 15.3 and estradiol in women with macrocystic disease of breast. Study in function of the type of cyst].
    Vizoso F; Allende MT; Díez MC; Ruibal A
    Rev Clin Esp; 1991 Nov; 189(8):390-1. PubMed ID: 1784805
    [No Abstract]   [Full Text] [Related]  

  • 4. [The correlation between the serum concentrations of BCM (breast cancer mucin), CA549 and estradiol in women with breast macrocysts].
    Vizoso F; Allende MT; Fueyo A; Ruibal A
    Med Clin (Barc); 1991 Feb; 96(5):198. PubMed ID: 2033998
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence of a correlation between CA15.3 and prolactin serum levels after TRH administration in women with gross cystic breast disease.
    Vizoso F; Allende MT; Fueyo A; Riera L; López Otin C; Ruibal A
    Int J Biol Markers; 1991; 6(1):31-2. PubMed ID: 1906915
    [No Abstract]   [Full Text] [Related]  

  • 6. [Correlation of serum concentrations of BCM and MCA, CA 549 and CA 15.3 in women with macrocystic disease of breast].
    Vizoso F; Roiz MC; Allende MT; Ruibal A
    Med Clin (Barc); 1990 Mar; 94(8):319. PubMed ID: 2342398
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation between BCM (breast cancer mucin) and CA 549 serum levels cystic breast disease.
    Allende MT; Vizoso F; Roiz MC; Fueyo A; Ruibal A
    Int J Biol Markers; 1990; 5(1):48-9. PubMed ID: 2230352
    [No Abstract]   [Full Text] [Related]  

  • 8. [The steroid and peptide hormone content of the blood in women with different forms of fibrocystic mastopathy].
    Serov VN; Tumilovich LG; Rozhkova NI; Samoĭlova TE
    Akush Ginekol (Mosk); 1988 Mar; (3):54-6. PubMed ID: 3400830
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy.
    Radowicki S; Kunicki M
    J Endocrinol Invest; 2009 Nov; 32(10):821-4. PubMed ID: 19602918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of selected hormonal parameters in patients with mastopathy in postmenopausal period].
    Mizia-Stec K; Zych F; Widala E
    Ginekol Pol; 1998 Feb; 69(2):56-61. PubMed ID: 9591381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal steroids and tumor antigens in plasma and cyst fluid of women with gross cystic breast disease.
    Inaudi P; De Leo V; Baldini S; D'Antona N
    Ann N Y Acad Sci; 1990; 586():117-20. PubMed ID: 2356994
    [No Abstract]   [Full Text] [Related]  

  • 12. CA 15.3 behaviour in cystic breast disease.
    Vizoso F; Allende MT; Fueyo A; Vigal G; García-Morán M; Ruibal A
    Int J Biol Markers; 1989; 4(3):181-2. PubMed ID: 2614087
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparison of ultrasonographic results of the breast with progesterone levels in women with fibrocystic mastopathy].
    Urbanowicz Z; Buchacz P; Poreba R; Noras K
    Ginekol Pol; 1996 Aug; 67(8):411-3. PubMed ID: 9139011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Depo-Provera treatment of mastopathy patients].
    Khomasuridze AG; Manusharova RA
    Lik Sprava; 1993; (10-12):104-6. PubMed ID: 8030291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormonal correlations in uterine myoma, internal endometriosis and diffuse mastopathy in patients with a retained biphasic menstrual cycle].
    Sokolova ZP
    Akush Ginekol (Mosk); 1982 Jun; (6):15-9. PubMed ID: 6812446
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mastopathy and breast cancer: is there a typical hormone profile?].
    Völker W; Leipert KP; Gehrlings H; Stauch G; von zur Mühlen A; Schneider J
    Geburtshilfe Frauenheilkd; 1986 May; 46(5):284-9. PubMed ID: 3087811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen in the serum of women with benign breast disease.
    Radowicki S; Kunicki M; Bandurska-Stankiewicz E
    Eur J Obstet Gynecol Reprod Biol; 2008 Jun; 138(2):212-6. PubMed ID: 17850950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
    England PC; Sellwood RA; Knyba RE; Irvine JD
    Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
    [No Abstract]   [Full Text] [Related]  

  • 19. [The correlation between the serum concentrations of CA 549 and CA 15.3 in patients with cystic breast disease].
    Allende MT; Vizoso F; Fueyo A; Ruibal A
    Rev Clin Esp; 1990; 187(3):152-3. PubMed ID: 2284494
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
    Yenisey C; Güner G
    Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.